---
title: "Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292816164.md"
description: "Aldeyra Therapeutics plans to request a Type D meeting with the FDA by the end of Q3 2026. This follows clarification requests regarding minutes from a June 10, 2026, Type A meeting concerning its reproxalap NDA for dry eye disease. The upcoming Type D meeting aims to discuss the potential resubmission of the New Drug Application."
datetime: "2026-07-15T20:53:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292816164.md)
  - [en](https://longbridge.com/en/news/292816164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292816164.md)
---

# Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission

**Aldeyra Therapeutics requested clarification on FDA minutes and plans a Type D meeting to discuss potential reproxalap NDA resubmission.**

**Key Highlights:**

-   Received FDA minutes from a June 10, 2026 Type A meeting regarding reproxalap NDA for dry eye disease.
-   On July 15, 2026 Aldeyra requested clarification of those minutes from the FDA.
-   Aldeyra intends to request a Type D meeting to discuss potential NDA resubmission.
-   Type D meeting is expected to occur by end of Q3 2026, advancing resubmission discussions.

Original SEC Filing: Aldeyra Therapeutics, Inc. \[ ALDX \] - 8-K - Jul. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALDX.US](https://longbridge.com/en/quote/ALDX.US.md)

## Related News & Research

- [Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update](https://longbridge.com/en/news/294357729.md)
- [Inhibikase swaps 18,030,000 shares for RA Capital pre-funded warrant in unregistered offering](https://longbridge.com/en/news/294255122.md)
- [RA Capital Management reports USD 412,776 Artiva Biotherapeutics common share purchase](https://longbridge.com/en/news/294116655.md)
- [Major Investor Doubles Down on Artiva Biotherapeutics With Bold New Move](https://longbridge.com/en/news/294143110.md)
- [EY study pegs Bond platform annual economic benefit at up to $280 per employee](https://longbridge.com/en/news/294208482.md)